Buy Adderall (Amphetamine, Dextroamphetamine) online

Buy Adderall (Amphetamine, Dextroamphetamine mixed salts) medication
Cheap qualitative psychostimulant medicine Adderall 30 mg tablets online



HOW AND WHERE TO BUY ADDERALL (AMPHETAMINE, DEXTROAMPHETAMINE MIXED SALTS) 30 MG TABLETS OR CAPSULES ONLINE:

ADDERALL-XR (AMPHETAMINE, DEXTROAMPHETAMINE): ADVERSE REACTIONS / SIDE EFFECTS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Clinical Trial Experience

The premarketing development program for Adderall-XR extended release capsules included exposures in a total of 1315 participants in clinical trials (635 pediatric patients, 350 adolescent patients, 248 adult patients, and 82 healthy adult subjects). Of these, 635 patients (ages 6 to 12) were evaluated in two controlled clinical studies, one open-label clinical study, and two single-dose clinical pharmacology studies (N=40). Safety data on all patients are included in the discussion that follows. Adverse reactions were assessed by collecting adverse reactions, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs.

Adverse reactions during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a smaller number of standardized event categories. In the tables and listings that follow, COSTART terminology has been used to classify reported adverse reactions.

The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed.

Adverse Reactions Leading to Discontinuation of Treatment

In two placebo-controlled studies of up to 5 weeks duration among children with ADHD, 2.4% (10/425) of Adderall-XR (Amphetamines with Dextroamphetamines) treated patients discontinued due to adverse reactions (including 3 patients with loss of appetite, one of whom also reported insomnia) compared to 2.7% (7/259) receiving placebo.

The most frequent adverse reactions leading to discontinuation of Amphetamine with Dextroamphetamine (Adderall-XR) in controlled and uncontrolled, multiple-dose clinical trials of children (N=595) were anorexia (loss of appetite) (2.9%), insomnia (1.5%), weight loss (1.2%), emotional lability (1%), and depression (0.7%). Over half of these patients were exposed to Amphetamines and Dextroamphetamines (Adderall-XR) for 12 months or more.

In a separate placebo-controlled 4-week study in adolescents with ADHD, five patients (2.1%) discontinued treatment due to adverse events among mixed salts of Amphetamine and Dextroamphetamine (Adderall-XR) treated patients (N=233) compared to none who received placebo (N=54). The most frequent adverse event leading to discontinuation and considered to be drug-related (i.e. leading to discontinuation in at least 1% of Adderall-XR treated patients and at a rate at least twice that of placebo) was insomnia (1.3%, n=3).

In one placebo-controlled 4-week study among adults with ADHD with doses 20 mg to 60 mg, 23 patients (12.0% ) discontinued treatment due to adverse events among Adderall-XR treated patients (N=191) compared to one patient (1.6%) who received placebo (N=64). The most frequent adverse events leading to discontinuation and considered to be drug-related (i.e. leading to discontinuation in at least 1% of Adderall-XR (Amphetamine, Dextroamphetamine) capsules treated patients and at a rate at least twice that of placebo) were insomnia (5.2%, n=10), anxiety (2.1%, n=4), nervousness (1.6%, n=3), dry mouth (1.6%, n=3), anorexia (1.6%, n=3), tachycardia (1.6%, n=3), headache (1.6%, n=3), and asthenia (1.0%, n=2).

Adverse Reactions Occurring in Controlled Trials

Adverse reactions reported in a 3-week clinical trial of children and a 4-week clinical trial in adolescents and adults, respectively, treated with Adderall-XR (Amphetamine, Dextroamphetamine) or placebo are presented in the tables below.

Adverse Reactions Reported by 2% or More of Children (6-12 Years Old) Receiving Adderall-XR (Amphetamine, Dextroamphetamine mixed salts) with Higher Incidence Than on Placebo in a 584-Patient Clinical Study:

General: fever, abdominal pain (stomachache), accidental injury, infection, asthenia (fatigue)

Digestive System: vomiting, nausea, loss of appetite, dyspepsia

Nervous System: emotional lability, insomnia, dizziness, nervousness

Metabolic / Nutritional: weight loss

Adverse Reactions Reported by 5% or More of Adolescents (13-17 Years Old) Weighing <= 75 kg/165 lbs Receiving Adderall-XR (Amphetamines) with Higher Incidence Than Placebo in a 287 Patient Clinical Forced Weekly-Dose Titration Study (included doses up to 40 mg):

General: abdominal pain (stomachache)

Digestive System: loss of appetite

Nervous System: insomnia, nervousness

Metabolic / Nutritional: weight loss

Note: The following reactions were reported by 2% to 4% of adolescent patients receiving Amphetamines (Adderall-XR) with a higher incidence than patients receiving placebo in this study: asthenia (fatigue), accidental injury, dry mouth, emotional lability, dyspepsia, nausea, vomiting, somnolence.

Adverse Reactions Reported by 5% or More of Adults Receiving Adderall-XR (Amphetamines) capsules with Higher Incidence Than on Placebo in a 255 Patient Clinical Forced Weekly-Dose Titration Study (included doses up to 60 mg):

General: asthenia, headache

Digestive System: loss of appetite, dry mouth, diarrhea, nausea

Nervous System: agitation, insomnia, dizziness, anxiety

Cardiovascular System: tachycardia

Metabolic / Nutritional: weight loss

Urogenital System: urinary tract infection

Note: The following reactions were reported by 2% to 4% of adult patients receiving Adderall-XR capsules with a higher incidence than patients receiving placebo in this study: photosensitivity reaction, infection, constipation, tooth disorder (e.g., teeth clenching, tooth infection), libido decreased, emotional lability, somnolence, speech disorder (e.g., stuttering, excessive speech), twitching, palpitation, dyspnea, dysmenorrhea, sweating, and impotence.

Hypertension

In a controlled 4-week outpatient clinical study of adolescents with ADHD, isolated systolic blood pressure elevations .15 mmHg were observed in 7/64 (11%) placebo-treated patients and 7/100 (7%) patients receiving Adderall-XR extended release capsules 10 or 20 mg. Isolated elevations in diastolic blood pressure >= 8 mmHg were observed in 16/64 (25%) placebo-treated patients and 22/100 (22%) Adderall-XR (Amphetamines with Dextroamphetamines) treated patients. Similar results were observed at higher doses.

In a single-dose pharmacokinetic study in 23 adolescents with ADHD, isolated increases in systolic blood pressure (above the upper 95% CI for age, gender, and stature) were observed in 2/17 (12%) and 8/23 (35%), subjects administered 10 mg and 20 mg Amphetamine with Dextroamphetamine (Adderall-XR), respectively. Higher single doses were associated with a greater increase in systolic blood pressure. All increases were transient, appeared maximal at 2 to 4 hours post dose and not associated with symptoms.

Adverse Reactions Associated with the Use of Amphetamine, Adderall-XR capsules, or Adderall tablets

The following adverse reactions have been associated with the use of amphetamine, Adderall-XR, or Adderall:

Cardiovascular

Palpitations. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.

Central Nervous System

Overstimulation, psychotic episodes at recommended doses, restlessness, dyskinesia, euphoria, dysphoria, depression, tremor.

Gastrointestinal

Unpleasant taste, constipation, other gastrointestinal disturbances.

Allergic

Urticaria, hypersensitivity reactions including angioedema and anaphylaxis, rash. Serious skin rashes, including Stevens-Johnson Syndrome and toxic epidermal necrolysis have been reported.

Endocrine

Impotence, changes in libido.



Adderall-XR related pharmaceutical drugs and medications

Trade name of the drug Pharmaceutical forms and doses Companies
Buspirona Genfar - Buspirone Hydrochloride
  • Tablets; Oral; Buspirone Hydrochloride 5 mg
  • Tablets; Oral; Buspirone Hydrochloride 10 mg
  • Genfar Laboratorios
  • Hydroxyzine Par - Hydroxyzine Pamoate
  • Capsules; Oral; Hydroxyzine Pamoate 25 mg
  • Capsules; Oral; Hydroxyzine Pamoate 50 mg
  • Capsules; Oral; Hydroxyzine Pamoate 100 mg
  • Par Pharmaceutical


  • Recent posts:

  • Buy Adderall-XR (Amphetamine, Dextroamphetamine) Online
  • Adderall-XR prescribing information

    Copyright © Buy Adderall Online